Renowned large Indian private laboratory chain Dr. Lal PathLabs implements TB-LAMP
Novel molecular technology in the fight against tuberculosis open up new opportunities in the Indian private sector.
Tuberculosis remains still a major health issue in India. With a TB incidence of 2,740,000 in 2017 (1,907,371 total notified cases) India is the leader throughout the 30 High Burden countries worldwide. In addition to the above mentioned number, each year more than 850,000 cases are missed – especially due to a lack of appropriate detection methods.
In addition to the governmental market, there is also a private sector in India, which accounts for a large part of the market at around 30-50 %. One of the private top diagnostic chains in India is Dr. Lal PathLabs. With a network of more than 190 laboratories, patients have access to reliable, high quality diagnostics and patient service not only in India, but also beyond the country's borders. Dr. Lal PathLabs has earned the reputation of being one of the most reliable pathology laboratories in India.
“The high sensitivity, high throughput and the reliability of the assay, even under the challenging climate conditions, have convinced us. Due to the fact that results can be generated in less than two hours, we can give our physicians faster clarity about the infection status of their patients. With this novel technology, we have the opportunity to find more Tuberculosis cases than with traditional methods” say experts at Dr. Lal PathLabs.
Since WHO recommendation at the end of 2016, TB-LAMP has been evaluated in more than 20 countries, especially in remote settings. “We are proud to be a partner of Dr. Lal PathLabs and to see the HumaLoop T in their National Reference Laboratory, Delhi, and also in Kolkata laboratories. Since accurate diagnosis is the first step to initiate a successful treatment, we are convinced that TB-LAMP can generate a significant contribution to the fight against TB in India” comments Andre Jendretzki, New Market & Business Development, HUMAN.
Dr. Lal PathLabs plans to extend the introduction of TB-LAMP to the whole of India in the coming months to provide even more physicians and patients with access to faster and more sensitive diagnostics.
The TB-LAMP solution, developed by our partner Eiken Chemical Co., Ltd., is a molecular method for the detection of Mycobacterium Tuberculosis Complex. More info: www.human.de/lamp
About Dr. Lal PathLabs
Dr. Lal PathLabs is an international service provider of quality diagnostic and healthcare tests with its base in Delhi. Founded in 1949, the laboratory chain established about 190 sites by now. www.lalpathlabs.com
About WHO and TB-LAMP
In 2016, WHO recommended that smear microscopy may be replaced by TB-LAMP (http://sho.rtlink.de/lamp).
HUMAN, founded in 1972, is a Germany based privately owned company which develops, manufactures and distributes a wide range of IVD Diagnostics and laboratory equipment. The comprehensive portfolio of more than 400 products covers almost all areas of modern laboratory including Autoimmune and Molecular Diagnostics. With its strong network of partners in 160 countries and with six regional offices around the globe, HUMAN maintains probably the broadest distribution and service network, especially in developing and emerging countries.
Dr. Gabriele Ackermann